Bristi Basu
0000-0002-3562-2868
Publication & Citation Trends
Publications
0 total
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors OA
Cited by 7
Semantic Scholar
Clinical trials for pancreatic cancer
Cited by 0
Semantic Scholar
Abstract LB192: MTL-CEBPA in combination with pembrolizumab converts an immune desert to an inflamed TME in solid tumors resistant to checkpoint blockade
Cited by 0
Semantic Scholar
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial OA
Cited by 34
Semantic Scholar
Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma OA
Cited by 10
Semantic Scholar
Surgical outcomes of gallbladder cancer: the OMEGA retrospective, multicentre, international cohort study OA
Cited by 44
Semantic Scholar
Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma OA
Cited by 6
Semantic Scholar
A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC).
Cited by 15
Semantic Scholar
Research Topics
Ovarian cancer diagnosis and treatment
(46)
Pancreatic and Hepatic Oncology Research
(38)
Colorectal Cancer Treatments and Studies
(26)
Cancer Genomics and Diagnostics
(23)
Hepatocellular Carcinoma Treatment and Prognosis
(22)
Affiliations
National Health Service
NHS Blood and Transplant
University of Leeds
Royal Marsden NHS Foundation Trust
MACOM (United States)